down arrow

MyMD Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US62856X1028
USD
5.13
-0.31 (-5.7%)

Dec 24

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

4.945.45

52 Week

2.50152.00
Valuation
Technical
Day's Volume

CASH

48.74 k

Shareholding (Mar 2025)

FII

0.09%

Held by 10 FIIs

DII

95.36%

Held by 5 DIIs

Promoter

0.00%

How big is MyMD Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, MyMD Pharmaceuticals, Inc. has a market capitalization of 2.12 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -14.68 million over the latest four quarters. The company's shareholder's funds are 14.72 million, and total assets are 21.42 million.

Market Cap: As of Jun 18, MyMD Pharmaceuticals, Inc. has a market capitalization of 2.12 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, MyMD Pharmaceuticals reported net sales of 0.00 million and a net profit of -14.68 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 14.72 million, while total assets were reported at 21.42 million.

Read More

What does MyMD Pharmaceuticals, Inc. do?

22-Jun-2025

MyMD Pharmaceuticals, Inc. develops and supplies point-of-care screening and testing products in the Pharmaceuticals & Biotechnology sector. It has a market cap of $2.12 million and reported a net profit loss of $1 million as of March 2025.

Overview:<BR>MyMD Pharmaceuticals, Inc. develops, manufactures, and supplies point-of-care screening and testing products in the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 2.12 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.42<BR>Return on Equity: -57.42%<BR>Price to Book: 0.15<BR><BR>Contact Details:<BR>Address: 201 Grove Rd, WEST DEPTFORD NJ: 08086-2231<BR>Tel: ['1 856 8488698', '1 646 5367331']<BR>Website: http://www.akersbio.com

Read More

Who are in the management team of MyMD Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of MyMD Pharmaceuticals, Inc. includes Mr. Joshua Silverman as Chairman of the Board, along with Independent Directors Mr. Robert Schroeder and Mr. Bill White.

As of March 2022, the management team of MyMD Pharmaceuticals, Inc. includes Mr. Joshua Silverman, who serves as the Chairman of the Board, along with Mr. Robert Schroeder and Mr. Bill White, both of whom are Independent Directors.

Read More

Is MyMD Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of May 11, 2020, MyMD Pharmaceuticals, Inc. is considered overvalued with a valuation grade of "does not qualify," reflecting poor financial metrics such as a -57.42% return on equity and an 88% year-to-date decline, especially when compared to its peers.

As of 11 May 2020, MyMD Pharmaceuticals, Inc. has moved from a valuation grade of risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently overvalued given its financial metrics, including a price-to-book value of 0.17 and an EV to EBITDA ratio of 0.42. Notably, the return on equity (ROE) stands at a concerning -57.42%, reflecting the company's struggles in generating returns for shareholders.<BR><BR>In comparison to its peers, MyMD Pharmaceuticals shows a stark contrast with Regulus Therapeutics, Inc., which has a P/E ratio of -11.9462, and Corbus Pharmaceuticals Holdings, Inc., with an EV to EBITDA of 0.5170. The overall peer group indicates that MyMD Pharmaceuticals is not only underperforming but also lacks the financial metrics to justify its current valuation. The company's stock has significantly underperformed against the S&P 500, with a year-to-date decline of 88.00%, further reinforcing the notion that it is overvalued in the current market environment.

Read More

Is MyMD Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, MyMD Pharmaceuticals, Inc. shows a mildly bullish trend overall, despite significant underperformance against the S&P 500 and several bearish indicators in daily moving averages and Bollinger Bands.

As of 11 September 2025, the technical trend for MyMD Pharmaceuticals, Inc. has changed from sideways to mildly bullish. The weekly and monthly MACD indicators are both mildly bullish, while the monthly RSI indicates a bullish stance. However, the daily moving averages are bearish, and both the weekly and monthly KST and Dow Theory indicators are bearish. The Bollinger Bands show a mildly bearish trend on the weekly and a bearish trend on the monthly. <BR><BR>In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -96.61% versus the S&P 500's 12.22%. Overall, the current technical stance is mildly bullish, but the strength is tempered by several bearish indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 7 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.33

stock-summary
Return on Equity

-68.30%

stock-summary
Price to Book

0.58

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
46.15%
0%
46.15%
6 Months
-62.83%
0%
-62.83%
1 Year
-96.02%
0%
-96.02%
2 Years
-99.27%
0%
-99.27%
3 Years
-99.84%
0%
-99.84%
4 Years
-99.97%
0%
-99.97%
5 Years
-99.96%
0%
-99.96%

MyMD Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-12.94%
EBIT Growth (5y)
0.94%
EBIT to Interest (avg)
-15.26
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.42
Sales to Capital Employed (avg)
-0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
14.69%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.17
EV to EBIT
0.42
EV to EBITDA
0.42
EV to Capital Employed
-0.44
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-57.42%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 6 Schemes (4.55%)

Foreign Institutions

Held by 10 Foreign Institutions (0.09%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 81.25% vs -128.57% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.90",
          "val2": "-1.90",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-7.70",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.80",
          "val2": "-9.60",
          "chgp": "81.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -485.00% vs 73.68% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.20",
          "val2": "-17.10",
          "chgp": "40.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-13.50",
          "val2": "12.70",
          "chgp": "-206.30%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-23.40",
          "val2": "-4.00",
          "chgp": "-485.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.90
-1.90
Interest
0.00
0.00
Exceptional Items
0.00
-7.70
100.00%
Consolidate Net Profit
-1.80
-9.60
81.25%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 81.25% vs -128.57% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-10.20
-17.10
40.35%
Interest
0.00
0.00
Exceptional Items
-13.50
12.70
-206.30%
Consolidate Net Profit
-23.40
-4.00
-485.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -485.00% vs 73.68% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About MyMD Pharmaceuticals, Inc. stock-summary
stock-summary
MyMD Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Akers Biosciences, Inc. develops, manufactures, and supplies point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician. The Company’s product offerings focus on delivering diagnostic assistance in a variety of healthcare fields/specialties, including diagnostic rapid manual point-of-care tests for the detection of allergic reactions to Heparin and for on- and off-the-job alcohol safety initiatives. The Company's primary focus is on the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company's main products include a disposable breathalyzer test that measures the blood alcohol content of the user, a rapid test detecting the antibody causing an allergic reaction to Heparin and a disposable breathalyzer test that measures Free Radical activity in the human body.
Company Coordinates stock-summary
Company Details
201 Grove Rd , WEST DEPTFORD NJ : 08086-2231
stock-summary
Tel: 1 856 84886981 646 5367331
stock-summary
http://www.akersbio.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."